STOCK TITAN

Monthly information on share capital and company voting rights

Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.

  • ISIN: FR0010425595
  • Date: 12/31/2025
  • Total shares: 100,339,441
  • Total voting rights: 105,576,356

Contact details for media and investor relations were provided for further information.

Loading...
Loading translation...
Argus Jan 6 session
-3.08% close to close 0.6x rel. volume Open Argus
Details

News Market Reaction – CLLS

On Jan 6, the first trading day after this news, CLLS closed 3.08% below the previous close.

Data tracked by StockTitan Argus for the Jan 6 session.

Key Figures

Total shares: 100,339,441 Total voting rights: 105,576,356
Total shares
100,339,441
Share capital as of 12/31/2025
Total voting rights
105,576,356
Voting rights as of 12/31/2025

Historical Context

5 past events · Latest: Dec 15
5 events
  1. Dec 15

    Arbitration outcome

    24h Move
    +2.4%

    Arbitral Tribunal decision partially terminating a license and dismissing other claims.

  2. Dec 08

    Clinical data update

    24h Move
    -2.5%

    ASH 2025 Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.

  3. Dec 03

    Capital/voting report

    24h Move
    +3.6%

    Monthly disclosure of total shares and voting rights as of November 30, 2025.

  4. Nov 19

    Scientific publication

    24h Move
    +7.1%

    Nature Communications paper on non-viral CssDNA gene insertion with high efficiency.

  5. Nov 07

    Earnings and update

    24h Move
    +11.3%

    Q3 2025 results with multiple CAR-T efficacy data points and stronger revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

isin
1 terms
isin financial
"Listing market: Euronext Growth ISIN code: FR0010425595"
A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Jan. 05, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting
rights
12/31/2025100,339,441105,576,356
   

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachment


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Cellectis (CLLS) total shares and voting rights as of December 31, 2025?

As of 12/31/2025, Cellectis reported 100,339,441 shares and 105,576,356 total voting rights.

Which market and ISIN does the Cellectis (CLLS) share capital notice reference?

The notice references Euronext Growth and ISIN FR0010425595.

Where can investors get more information about Cellectis (CLLS) share capital on January 5, 2026?

Investors can contact the provided investor relations email at investors@cellectis.com or the CFO contact listed in the release.

Does the December 31, 2025 report for Cellectis (CLLS) show a change in share count or voting rights?

The release provides the recorded totals for 12/31/2025; it does not include prior-period figures or an explicit change comparison.

Who are the media contacts listed for Cellectis (CLLS) regarding the December 2025 voting rights report?

Media contacts listed are Pascalyne Wilson and Patricia Sosa Navarro with phone numbers provided in the notice.

Keep reading